Introduction: In breast cancer patients, menopausal symptoms are often reached earlier and in a more severe manner than in healthy women. They can dramatically reduce a patient’s quality of life. Treatment for breast cancer patients remains difficult due to hormone replacement therapy being contraindicated. Therefore, treatment alternatives like herbal phytoestrogen preparations are considered to be a treatment option. Methods: All randomized controlled trials (RCTs) that investigated comparisons of food products, extracts, or dietary supplements containing phytoestrogens in women with a diagnosis of breast cancer were included in the analysis. Results: There was no evidence that phytoestrogen preparations had a benefit over placebo in the treatment of breast cancer patients with menopausal symptoms. Neither the frequency nor severity of menopausal symptoms and the quality of life or occurrence of adverse events were reduced in comparison to a placebo. Conclusion: As we cannot prove a benefit of plant extracts in the treatment of menopausal symptoms in breast cancer patients, different herbal preparations should be analyzed in RCTs in order to find sufficient and safe new treatment options for symptomatic menopausal breast cancer patients. A focus should also be laid on developing a core outcome set to simplify pooling of different studies.

Keywords:
Phytoestrogens, Menopause, Breast cancer
1.
Takahashi TA, Johnson KM Med Clin North Am. 2015 May;99(3):521–34.
2.
Gracia CR, Freeman EW. Onset of the menopause transition: the earliest signs and symptoms. Obstet Gynecol Clin North Am. 2018 Dec;45(4):585–97. Epub 2018 Oct 25.
3.
Blumel JE, Castelo-Branco C, Binfa L, Gramegna G, Tacla X, Aracena B, et al. Quality of life after the menopause: a population study. Maturitas. 2000 Jan 15;34:17–23.
4.
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15;144(8):1941–53. Epub 2018 Dec 6.
5.
Mar Fan HG, Houede-Tchen N, Chemerynsky I, Yi QL, Xu W, Harvey B, et al. Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study. Ann Oncol. 2010;21(5):983–7.
6.
Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol. 1995;13(11):2737–44.
7.
Freeman EW. Associations of depression with the transition to menopause. Menopause. 2010;17(4):823–7.
8.
Hickey M, Saunders C, Partridge A, Santoro N, Joffe H, Stearns V. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol. 2008;19(10):1669–80.
9.
Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2008;107(2):167–80.
10.
Lemij AA, de Glas NA, Derks MGM, Bastiaannet E, Merkus JWS, Lans TE, et al. Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer. Breast Cancer Res Treat. 2022;193(3):567–77.
11.
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017 Jul;24(7):728–53.
12.
Tham DM, Gardner CD, Haskell WL. Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab. 1998;83(7):2223–35.
13.
Bruno D, Feeney KJ. Management of postmenopausal symptoms in breast cancer survivors. Semin Oncol. 2006 Dec;33(6):696–707.
14.
Baber R, Hickey M, Kwik M. Therapy for menopausal symptoms during and after treatment for breast cancer : safety considerations. Drug Saf. 2005;28(12):1085–100.
15.
MacGregor CA, Canney PA, Patterson G, McDonald R, Paul J. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer. 2005 Mar;41(5):708–14.
16.
Ferraris C, Ballestra B, Listorti C, Cappelletti V, Reduzzi C, Scaperrotta GP, et al. Red clover and lifestyle changes to contrast menopausal symptoms in premenopausal patients with hormone-sensitive breast cancer receiving tamoxifen. Breast Cancer Res Treat. 2020 Feb;180(1):157–65. Epub 2020 Jan 24.
17.
Nikander E, Kilkkinen A, Metsä-Heikkilä M, Adlercreutz H, Pietinen P, Tiitinen A, et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol. 2003 Jun;101(6):1213–20.
18.
Quella SK, Loprinzi CL, Barton DL, Knost JA, Sloan JA, LaVasseur BI, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol. 2000 Mar;18(5):1068–74.
19.
Basu P, Maier C. Phytoestrogens and breast cancer: in vitro anticancer activities of isoflavones, lignans, coumestans, stilbenes and their analogs and derivatives. Biomed Pharmacother. 2018 Nov;107:1648–66. Epub 2018 Sep.
20.
Chen MN, Lin CC, Liu CF. Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review. Climacteric. 2015 Apr;18(2):260–9.
21.
Rice S, Whitehead SA. Phytoestrogens and breast cancer: promoters or protectors? Endocr Relat Cancer. 2006 Dec;13(4):995–1015.
22.
Peng CC, Liu CY, Kuo NR, Tung TH. Effects of phytoestrogen supplement on quality of life of postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2019 Apr 1;2019:3261280.
23.
Duffy C, Perez K, Partridge A. Implications of phytoestrogen intake for breast cancer. CA Cancer J Clin. 2007 Sep–Oct;57(5):260–77.
24.
Alipour S, Jafari-Adli S, Eskandari A. Benefits and harms of phytoestrogen consumption in breast cancer survivors. Asian Pac J Cancer Prev. 2015;16(8):3091–396.
25.
Duffy JMN, Cairns AE, Richards-Doran D, van't Hooft J, Gale C, Brown M, et al. A core outcome set for pre-eclampsia research: an international consensus development study. BJOG. 2020;127(12):1516–26.
26.
Duffy JMN, AlAhwany H, Bhattacharya S, Collura B, Curtis C, Evers JLH, et al. Developing a core outcome set for future infertility research: an international consensus development study. Hum Reprod. 2020 Dec;35(12):2725–34.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.